Product Description
Caricotamide is a synthetic co-substrate that activates the human endogenous enzyme NRH:quinone oxidoreductase 2 (NQO2) with potential chemoadjuvant activity (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Caricotamide)
Mechanisms of Action: QOR Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Protherics Development Medicines Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PR003-CLN-pro001 | P2 |
Terminated |
Hepatocellular Carcinoma |
2009-06-01 |
|
2008-000912-34 | P2 |
Completed |
Hepatocellular Carcinoma |
2009-03-05 |